Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function

Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve

1978 • 613 citations

Human cytochromes P450: problems and prospects

1992 • 364 citations

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

1992 • 363 citations

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability

1994 • 316 citations

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

1992 • 128 citations

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1994 • 127 citations

Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man

1987 • 98 citations

Etoposide pharmacokinetics in patients with normal and abnormal organ function.

1986 • 94 citations

Reduced Albumin Binding Promotes the Stability and Activity of Topotecan in Human Blood

1995 • 92 citations

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

1994 • 86 citations

Design of Experiments in Non-Linear Situations

1959 • 77 citations

Age-related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine

1991 • 48 citations

Simultaneous administration of multiple model substrates to assess hepatic drug clearance

1987 • 35 citations

Extended Least Squares (ELS) for Pharmacokinetic Models

1987 • 31 citations

Simultaneous analysis of antipyrine and lorazepam by high-performance liquid chromatography

1986 • 23 citations

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1994 • 4 citations

Cited By (0)

Loading...